tiprankstipranks
Akari Therapeutics reports FY22 EPS 0c vs 0c last year
The Fly

Akari Therapeutics reports FY22 EPS 0c vs 0c last year

"Nomacopan’s distinctive dual mechanism of action against two key proinflammatory mediators, C5 and LTB4, we believe has blockbuster potential with the versatility to take the complement inhibitor category to the next level across multiple rare diseases and mass markets," said Rachelle Jacques, Akari President and CEO. "During the last twelve months, Akari has made significant progress in realizing the promise of this novel asset by advancing to the registrational part of the Phase 3 clinical trials in pediatric HSCT-TMA and toward a regulatory filing for PAS-nomacopan to begin clinical trials in GA in the first half of 2024."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AKTX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles